An Unlikely Cancer Ally
Researchers have uncovered a remarkable synergy between telmisartan, a well-established medication for high blood pressure, and olaparib, a targeted cancer
therapy. This combination therapy demonstrates a significantly amplified tumor-killing effect, offering new hope for cancer patients. The study, published in The Journal for ImmunoTherapy of Cancer, highlights that this common, safe, and affordable drug could potentially make a major class of cancer treatments, known as PARP inhibitors, more effective for a broader patient population, including those who previously did not respond to these therapies or have developed resistance over time. The implications are substantial, suggesting a low-cost adjunct that could dramatically improve treatment outcomes.
Mechanism of Action
PARP inhibitors, such as olaparib, are designed to exploit weaknesses in cancer cells' DNA repair mechanisms, particularly in tumors with specific genetic mutations like BRCA. However, their effectiveness is limited to certain cancer types and many patients eventually develop resistance. The groundbreaking research from Dartmouth Cancer Center reveals that telmisartan can enhance the sensitivity of tumors to PARP inhibitors, even in cancers that do not possess the typical DNA repair defects. Preclinical tests showed that combining telmisartan with olaparib led to more extensive DNA damage in tumors compared to olaparib alone. Crucially, this combination also triggered robust immune responses, notably increasing the production of type I interferons, molecules that are vital for the immune system to identify and combat cancer cells. This immune activation is believed to be a key driver of the enhanced therapeutic benefits.
Telmisartan's Unique Role
Within the class of angiotensin II receptor blockers (ARBs) commonly used for hypertension, telmisartan stood out in the study for its cancer-boosting capabilities. Beyond its impact on DNA damage and immune signaling, telmisartan was observed to reduce levels of PD-L1 within tumor cells. PD-L1 is a protein that cancer cells often use to evade detection and attack by the immune system. By lowering PD-L1, telmisartan may further enhance the effectiveness of cancer treatments. Scientists believe telmisartan possesses several distinct anticancer properties that, when combined with targeted therapies, can make tumors more receptive to various treatments. Preliminary data also suggests telmisartan could improve the efficacy of different chemotherapy agents and immunotherapies across numerous cancer types through similar underlying mechanisms.
Clinical Trials Underway
Given telmisartan's favorable safety profile, ease of oral administration, and widespread tolerability, it is an ideal candidate for clinical evaluation in cancer patients. Dartmouth Cancer Center is actively pursuing this potential, with two ongoing clinical trials investigating this combination therapy. One trial is evaluating telmisartan in conjunction with olaparib for men diagnosed with metastatic, castration-resistant prostate cancer, with early results indicating an exceptional response in the first participant. Another trial is focusing on platinum-resistant ovarian cancer, also incorporating telmisartan into the treatment regimen, and has recently enrolled its initial patient. These trials aim to ascertain whether this combined approach can improve patient outcomes by enhancing the effectiveness of PARP inhibitors and other cancer treatments, and potentially overcoming existing drug resistance.
